Publications in collaboration with researchers from Swedish Institute for Health Economics (2)

2019

  1. Updated Cost-effectiveness Analysis of Evolocumab in Patients with Very High-risk Atherosclerotic Cardiovascular Disease

    JAMA Cardiology

2017

  1. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain

    Clinical Therapeutics, Vol. 39, Núm. 4, pp. 771-786.e3